EU/3/18/1988

Table of contents

About

On 22 February 2018, orphan designation (EU/3/18/1988) was granted by the European Commission to Chiesi Farmaceutici S.p.A., Italy, for (R)-2-(5-cyano-2-(6-(methoxycarbonyl)-7-methyl-3-oxo-8-(3-(trifluoromethyl)phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine-5-yl)phenyl)-N,N,N-trimethylethanaminium methanesulfonate dehydrate (also known as CHF6333) for the treatment of cystic fibrosis.

Key facts

Active substance
(R)-2-(5-cyano-2-(6-(methoxycarbonyl)-7-methyl-3-oxo-8-(3-(trifluoromethyl)phenyl)-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine-5-yl)phenyl)-N,N,N-trimethylethanaminium methanesulfonate dehydrate
Disease / condition
Treatment of cystic fibrosis
Date of decision
22/02/2018
Outcome
Positive
Orphan decision number
EU/3/18/1988

Sponsor's contact details

Chiesi Farmaceutici S.p.A.
Via Palermo 26/A
43122 Parma
Italy
Tel. +39 0521 279 793
E-mail: info@chiesigroup.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating